(Ovarian Cancer) Efficacy of Niraparib Monotherapy

From September 27 to October 1, 2019, Antonio González Martín presented at the European Society for Medical Oncology (ESMO) conference in Barcelona, Spain, the "Efficacy and Safety Evaluation Results of PARP Inhibitor Niraparib Monotherapy in Ovarian Cancer Patients in a Phase III Clinical Trial."

This Phase III clinical trial enrolled patients diagnosed with ovarian cancer, randomly assigning them to either the Niraparib 300mg once-daily monotherapy group (N=487) or the placebo group (N=246). The primary endpoint was progression-free survival (PFS). Approximately 50% of participating patients had homologous recombination deficiency (HRD).

Trial results: The median PFS (primary endpoint) was 13.8 months for the Niraparib group vs. 8.2 months for the placebo group, with a 38% reduction in PFS risk (HR 0.62), showing significant improvement.

Subgroup analysis: For homologous recombination-deficient patients, the median PFS was 21.9 months for the Niraparib group vs. 10.4 months for the placebo group, with a 57% reduction in PFS risk (HR 0.43), showing significant improvement.

Safety: The most commonly observed grade 3 or higher adverse events were anemia (31%), thrombocytopenia (29%), and neutropenia (13%). No patients died due to adverse events.

Based on the Phase III trial results, Antonio González Martín concluded: "PARP inhibitor Niraparib monotherapy improved progression-free survival in both overall ovarian cancer patients and those with homologous recombination deficiency."

Source: Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced Ovarian Cancer [ESMO 2019 Oncology News]

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Ovarian cancer